NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) announced on November 10, 2026, that Amir F. Heshmatpour, the Company’s Executive Chairman, President, and Chief Executive Officer, purchased an aggregate of 80,000 shares of common stock in open-market transactions on November 5, 6, and 9, 2026.
The purchases totaled $269,082 based on reported prices, at a weighted average of approximately $3.36 per share. Heshmatpour used personal funds for the transactions, and the Company did not issue any shares in connection with the purchase.
The filing notes that Heshmatpour has accumulated 271,000 shares through open-market purchases across April, May, August, September, and November 2026. Of these, 191,000 shares were purchased for approximately $688,000 following the Company’s August 12 announcement of topline Phase 2a results for intranasal NEO100.
In a statement regarding the purchases, Heshmatpour stated, “I’ve invested more than $1 million of my own money in NeOnc shares this year.” He added that he has added to his position repeatedly because he believes in the long-term potential of NEO100 and NEO212 for patients with brain cancer.
Separately, the Company reported that on November 11, 2026, the U.S. Food and Drug Administration granted a Type B End-of-Phase meeting to discuss a potential accelerated approval pathway for intranasal NEO100 in recurrent or progressive IDH-mutant grade 4 astrocytoma. This meeting is scheduled for early January 2027.
